Menu
Directory
Directory

COVID Frontline

Directory

Tackling COVID-19 and its Viral Variants on the Frontline with New Vaccines and Novel Monoclonal Antibody Treatments

Calendar
When:
June 2, 2021 @ 4:23 pm – June 2, 2022 @ 5:23 pm
2021-06-02T16:23:00+00:00
2022-06-02T17:23:00+00:00
ECHOS Online Programs

Program Modules

 

Part 1:
Tackling COVID-19 and its Viral Variants on the Frontline with New Vaccines and Novel Monoclonal Antibody Treatments Part 2:
Tackling COVID-19 and its Viral Variants on the Frontline with New Vaccines and Novel Monoclonal Antibody Treatments

FACULTY

Shyam Kottilil MD, PhD
Professor of Medicine
Chief, Division of Infectious Diseases
Institute of Human Virology
University of Maryland
Baltimore, MD

 

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Lilly, Merck & Co., Inc., Pfizer and Regeneron Pharmaceuticals, Inc.

mlg-logo
Copyright © 2019 Med Learning Group. Built by Divigner. All Rights Reserved.
Scroll to Top
Directory
Menu

Updates in the Treatment and Prevention of COVID-19​

Molnupiravir, an Oral Antiviral, Reduced the Risk of Hospitalization or Death in Patients with Mild-to-Moderate COVID-19

Molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death by 50% in an interim analysis of the phase 3 MOVe-OUT trial. The planned analysis evaluated data from 775 at-risk, non-hospitalized adult patients with mild-to-moderate COVID-19. All patients enrolled had at least one risk factor associated with poor COVID-19 outcomes and were randomized within 5 days of symptom onset. At day 29, 7.3% of patients who received molnupiravir were either hospitalized or died, compared with 14.1% of placebo-treated patients (P= .0012). No deaths were reported in patients receiving molnupiravir, compared with 8 deaths in patients who received placebo. The incidence of any adverse event was comparable in the molnupiravir and placebo groups (35% and 40%, respectively). Discontinuation due to adverse events was lower with molnupiravir (1.3%) versus placebo (3.4%).

Reference:

https://www.contagionlive.com/view/molnupiravir-could-become-first-authorized-covid-19-pill